In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

1. Ocio, E.M.
2. Vilanova, D.
3. Atadja, P.
4. Maiso, P.
5. Crusoe, E.
6. Fernández-Lázaro, D.
7. Garayoa, M.
8. San-Segundo, L.
9. Hernández-Iglesias, T.
10. de Álava, E.
11. Shao, W.
12. Yao, Y.-M.
13. Pandiella, A.
14. San-Miguel, J.F.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.3324/HAEMATOL.2009.015495 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus